Zymeworks Inc. announced it will report Q3 2026 financial results on November 9, 2026, without a conference call. The company will participate in multiple investor conferences in November, including events hosted by Wolfe Research, Stifel, Truist Securities, and Jefferies in New York and London. The biotech company continues executing its strategy of building a diversified portfolio of healthcare assets including commercial products like YUPELRI® and pipeline candidates.

Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI to its portfolio and providing durable cash flows. The company updated 2026 guidance to $278-292 million in total revenue and $114-128 million in Adjusted EBITDA. The acquisition is expected to deliver mid-teens IRR with immediate accretive revenue and cash flow, financed through a $350 million non-recourse note from OMERS and $217.5 million in existing cash.

Jazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.

Zymeworks Inc. announced it will report second quarter 2026 financial results on August 6, 2026, but will not host an earnings conference call due to its pending acquisition of Theravance Biopharma. The company plans to provide updates on the combined business following the expected closing of the acquisition.

Zymeworks announced a definitive agreement to acquire Theravance Biopharma for $17 per share ($929 million) to gain YUPELRI®, a nebulized LAMA for COPD treatment. The acquisition is financed through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' cash, with the deal expected to be accretive to earnings and cash flow. YUPELRI® generated $266.6 million in U.S. net sales in 2025 with 12% growth, positioning Zymeworks to diversify its revenue streams and fund R&D initiatives.

Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 78.6% in FRα-positive platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients. The drug demonstrated a favorable tolerability profile with median progression-free survival of 7.6 months across ovarian and endometrial cancer cohorts. Patient recruitment in dose optimization cohorts has been completed, supporting continued clinical development.

Zymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.

Zymeworks announced six poster presentations at AACR 2026 showcasing preclinical data from its antibody-drug conjugate (ADC) pipeline, including novel RAS-targeting platforms and multiple first-in-class programs. The company highlighted efficacy and favorable tolerability across solid tumor models, with clinical data from the Phase 1 ZW191 trial to be presented in an oral presentation on April 21.

Zymeworks Inc. announced the full-time appointments of Dr. Adam Schayowitz as Executive Vice President and Head of R&D, and Scott Platshon as Executive Vice President and Chief Business Officer, effective April 9, 2026. Both executives, previously in interim roles, will report to CEO Kenneth Galbraith. The appointments come as Zymeworks focuses on executing its pipeline strategy, managing licensed assets including Ziihera® (zanidatamab-hrii) and pasritamig, and advancing its asset aggregation strategy to drive long-term shareholder value.

Zymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executing strategic priorities.

Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα) for treating advanced or metastatic platinum-resistant ovarian cancer. The designation expedites development and review timelines for drugs addressing serious conditions with unmet medical needs. ZW191 is currently in Phase 1 clinical trials evaluating safety, tolerability, and anti-tumor activity in patients with advanced solid tumors.

Zymeworks Inc. announced that management will participate in upcoming investor conferences including the Needham 25th Annual Virtual Healthcare Conference on April 15 and the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21 in Toronto. The company will present clinical and preclinical data on its pipeline programs.